Company news
Recce Pharmaceuticals Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Anti-Viral Patent Granted in Hong Kong
April 11, 2022
Positive safety data from 4th Cohort -Phase I Clinical Trial
March 29, 2022
$3.08m R&D Rebate Received
March 28, 2022
Safety Committee Clears PhI R327 Dose Increase
March 6, 2022
S&P DJI Announces March 2022 Quarterly Rebalance
March 4, 2022
Positive Safety Continues in 3rd Cohort PhI Clinical Trial
February 20, 2022
Positive Safety Data from Third Cohort of PI Clinical Trial
February 7, 2022
Positive Safety Data from Second Cohort of PI Clinical Trial
January 18, 2022
Positive Safety Data from Phase 1 Clinical Trial
January 6, 2022
Patients to be Dosed in Ph 1 IV Clinical Trial of R327
December 14, 2021
Update on Phase I/II Clinical Trial for Burn Wound Infection
December 6, 2021
Appendix 4C and Activity Report
October 29, 2021
Ethics Approval to Start Phase 1 Intravenous Clinical Trial
October 24, 2021
Reinstatement to Official Quotation
October 12, 2021
Court Orders Granted
October 11, 2021
Suspension from Official Quotation
October 11, 2021
Trading halt
October 8, 2021
R327 Phase I Clinical Trial Registered on ANZCTR
September 30, 2021
Recce Receives Further Innovation Connections Grant
August 11, 2021
Anti-Viral Patent Granted in USA for RECCE Anti-Infectives
July 22, 2021
Anti-Viral Patent Granted in China
July 20, 2021
Outstanding Efficacy Against Flesh-Eating Bacteria
July 19, 2021
Multiple Patients Dosed in Topical Phase I/II Clinical Trial
July 11, 2021
Recce Clinical Pipeline Update
June 7, 2021
R327 Demonstrates World First Multiple Mechanisms of Action
May 27, 2021
R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO
May 19, 2021
Positive Data on RECCE 327 Against All Six ESKAPE Pathogens
May 3, 2021
RECCE 327 Registered for Topical Burns Study in Humans
April 15, 2021
Positive Sinusitis Patient Update - Special Access Scheme
April 7, 2021
Positive Sinusitis Data Against Infection
March 31, 2021
Anti-Viral Patent Granted in EU for RECCE Anti-Infectives
March 30, 2021
S&P DJI Announces March 2021 Quarterly Rebalance
March 12, 2021
Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange
March 7, 2021
Appendix 4D and Half Yearly Report
February 25, 2021
Recce Applies for Dual Listing on Frankfurt Stock Exchange
February 23, 2021
Fiona Stanley Hospital Phase I/II Clinical Trial Agreement
February 15, 2021
Further Encouraging COVID Results at Doherty
February 11, 2021
R&D Incentive Rebate Received
February 3, 2021
Positive Intranasal Animal Data against SARS-CoV-2 in Study
December 22, 2020
RCE Awarded AusIndustry Advanced Overseas Anti-Viral Finding
December 7, 2020
Recce Awarded AusIndustry Advanced Overseas (R&D) Finding
November 25, 2020
Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives
November 22, 2020
Encouraging Results Against SARS-CoV-2 Virus
November 10, 2020
HREC Approval to Start Phase I/II Burns Wound Study
October 15, 2020
Murdoch Childrens Research Institute, R435 Against H.Pylori
September 30, 2020
Recce Completes Capital Raising of $27.95m
September 23, 2020
R327 Phase I Study - Australias CMAX Clinical Facility
September 10, 2020
Positive & Concentration-Dependent Efficacy Against COVID-19
September 8, 2020
Recce Pharmaceuticals Receives Innovation Connections Grant
August 31, 2020
Recce Pharmaceuticals Appoints James Graham as CEO
August 28, 2020
Decks
The 5 newest of 45 decks. Every deck is listed under its year.
- Shareholder Meeting (November 2026)
Shareholder meeting · 19 slides · Nov 6, 2026
- Investor Presentation (November 2026)
Investor deck · 45 slides · November 2026
- Investor Presentation (October 2026)
Investor deck · 42 slides · October 2026
- Shareholder Meeting (September 2026)
Shareholder meeting · 10 slides · Sep 2, 2026
- Investor Presentation (September 2026)
Investor deck · 42 slides · September 2026